94 related articles for article (PubMed ID: 23364583)
1. 'Shedding' light on mechanisms of hyperphosphatemic vascular dysfunction.
Burger D; Levin A
Kidney Int; 2013 Feb; 83(2):187-9. PubMed ID: 23364583
[TBL] [Abstract][Full Text] [Related]
2. High phosphate directly affects endothelial function by downregulating annexin II.
Di Marco GS; König M; Stock C; Wiesinger A; Hillebrand U; Reiermann S; Reuter S; Amler S; Köhler G; Buck F; Fobker M; Kümpers P; Oberleithner H; Hausberg M; Lang D; Pavenstädt H; Brand M
Kidney Int; 2013 Feb; 83(2):213-22. PubMed ID: 22913982
[TBL] [Abstract][Full Text] [Related]
3. Ornithine is a key mediator in hyperphosphatemia-mediated human umbilical vein endothelial cell apoptosis: Insights gained from metabolomics.
Zhou R; Kang X; Tang B; Mohan C; Wu T; Peng A; Liu JY
Life Sci; 2016 Feb; 146():73-80. PubMed ID: 26773858
[TBL] [Abstract][Full Text] [Related]
4. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.
Zhou C; Wang F; Wang JW; Zhang LX; Zhao MH
Chin Med J (Engl); 2016 Oct; 129(19):2275-80. PubMed ID: 27647184
[TBL] [Abstract][Full Text] [Related]
5. [Pathogenesis and clinical condition of hyperphosphatemic diseases].
Hamano N; Fukagawa M
Clin Calcium; 2016 Feb; 26(2):207-13. PubMed ID: 26813500
[TBL] [Abstract][Full Text] [Related]
6. [Hyperphosphatemia in Chronic Kidney Disease (CKD)].
Wang J; Zhang XY; Guan YF
Sheng Li Ke Xue Jin Zhan; 2015 Aug; 46(4):241-4. PubMed ID: 26669072
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.
Six I; Maizel J; Barreto FC; Rangrez AY; Dupont S; Slama M; Tribouilloy C; Choukroun G; Mazière JC; Bode-Boeger S; Kielstein JT; Drüeke TB; Massy ZA
Cardiovasc Res; 2012 Oct; 96(1):130-9. PubMed ID: 22822101
[TBL] [Abstract][Full Text] [Related]
8. Extracellular regulated protein kinases play a key role via bone morphogenetic protein 4 in high phosphate-induced endothelial cell apoptosis.
Qin L; Tang B; Deng B; Mohan C; Wu T; Peng A
Life Sci; 2015 Jun; 131():37-43. PubMed ID: 25896660
[TBL] [Abstract][Full Text] [Related]
9. CD147 regulates cancer migration via direct interaction with Annexin A2 and DOCK3-β-catenin-WAVE2 signaling.
Cui HY; Wang SJ; Miao JY; Fu ZG; Feng F; Wu J; Yang XM; Chen ZN; Jiang JL
Oncotarget; 2016 Feb; 7(5):5613-29. PubMed ID: 26716413
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Tatsumoto N; Yamada S; Tokumoto M; Eriguchi M; Noguchi H; Torisu K; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F967-79. PubMed ID: 26336165
[TBL] [Abstract][Full Text] [Related]
11. Vascular calcification in chronic kidney disease.
Jono S; Shioi A; Ikari Y; Nishizawa Y
J Bone Miner Metab; 2006; 24(2):176-81. PubMed ID: 16502129
[TBL] [Abstract][Full Text] [Related]
12. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
[TBL] [Abstract][Full Text] [Related]
13. Damage of the endothelial glycocalyx in chronic kidney disease.
Padberg JS; Wiesinger A; di Marco GS; Reuter S; Grabner A; Kentrup D; Lukasz A; Oberleithner H; Pavenstädt H; Brand M; Kümpers P
Atherosclerosis; 2014 Jun; 234(2):335-43. PubMed ID: 24727235
[TBL] [Abstract][Full Text] [Related]
14. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Locatelli F; Del Vecchio L
J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
[TBL] [Abstract][Full Text] [Related]
15. Hyperphosphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells.
Abbasian N; Burton JO; Herbert KE; Tregunna BE; Brown JR; Ghaderi-Najafabadi M; Brunskill NJ; Goodall AH; Bevington A
J Am Soc Nephrol; 2015 Sep; 26(9):2152-62. PubMed ID: 25745026
[TBL] [Abstract][Full Text] [Related]
16. Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma.
Onishi M; Ichikawa T; Kurozumi K; Inoue S; Maruo T; Otani Y; Fujii K; Ishida J; Shimazu Y; Yoshida K; Michiue H; Antonio Chiocca E; Date I
Brain Tumor Pathol; 2015 Jul; 32(3):184-94. PubMed ID: 25697644
[TBL] [Abstract][Full Text] [Related]
17. Endothelial dysfunction and chronic kidney disease: treatment options.
Wu-Wong JR
Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
[TBL] [Abstract][Full Text] [Related]
18. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
[TBL] [Abstract][Full Text] [Related]
19. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
20. [Hyperphosphatemia and cardiovascular diseases : impact of vascular calcification and endothelial dysfunction].
Iijima K
Clin Calcium; 2012 Oct; 22(10):1505-13. PubMed ID: 23023630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
